Description
Is Ibruxen 140 mg right for your situation?
Review these criteria with your oncologist before enquiring- ✓Diagnosed with CLL, SLL, MCL, or Waldenström’s macroglobulinemia
- ✓Oncologist recommended a daily oral BTK inhibitor
- ✓Need a WHO-GMP generic alternative to Imbruvica®
- ✓Hold a valid oncologist prescription
- ✗On strong blood thinners (warfarin) or severe bleeding history
- ✗Uncontrolled atrial fibrillation or severe liver disease
- ✗Pregnant, planning pregnancy, or breastfeeding
- ✗Regular grapefruit consumer (CYP3A4 interaction)
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Ibruxen 140 mg?
Ibruxen 140 mg is a generic formulation of Ibrutinib — a Bruton’s Tyrosine Kinase (BTK) inhibitor — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. It contains the same active molecule as Imbruvica® (Pfizer/Janssen) and is dispensed under the Named Patient Program for patients requiring an affordable, quality-assured alternative.
| Generic name | Ibrutinib |
| Reference brand | Imbruvica® (Pfizer / Janssen) |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | BTK Inhibitor |
| Dosage form | Hard capsule — 140 mg |
| Pack sizes | 12’s strip / 90’s pot |
| Route | Oral · once daily |
| Prescription | Required — oncologist only |
How Ibrutinib Works
In blood cancers like CLL, the BTK (Bruton’s Tyrosine Kinase) pathway is overactive — cancer cells exploit it to survive and multiply. Ibrutinib permanently blocks BTK at the Cys481 residue, cutting off this survival signal.
What to Expect: First 30 Days
Every patient responds differently. Below is the typical early pattern your care team will guide you through.
- Week 1: Mild nausea, fatigue, or easy bruising may appear. A temporary white blood cell spike is normal and expected — it means the drug is working, pushing cancer cells out of lymph nodes into the bloodstream to be cleared.
- Weeks 2–3: Mild diarrhoea, muscle aches, or light rash may emerge. Blood tests monitor your cell counts and kidney function — keep all scheduled appointments.
- Week 4: Your body adjusts. Many patients report improved energy, and oncologists often see measurable reduction in swollen lymph nodes or an enlarged spleen on imaging.
Side Effects
Side effects vary by individual. Most are manageable with early guidance. Always report new symptoms to your oncologist promptly.
Common · Usually Manageable
- Diarrhoea or upset stomach
- Fatigue and weakness
- Muscle or joint pain
- Minor bruising or petechiae
- Mild skin rash
- Headache · high blood pressure
Serious · Report Immediately
- Major bleeding episodes
- Atrial fibrillation
- Severe infections
- Tumour lysis syndrome
- Elevated liver enzymes
- Blood in stool, urine, or coughing up blood
- Racing, fluttering, or highly irregular heartbeat
- High fever, chills, or sudden difficulty breathing
How to Take Ibruxen 140 mg
Typical CLL/SLL dose: 3 capsules (420 mg) once daily. Your oncologist confirms your exact schedule.
- 1Once daily — at the same time each day for consistency.
- 2Swallow whole with a full glass of water. Do not open, crush, break, or dissolve capsules.
- 3With or without food — avoid grapefruit and Seville oranges entirely (CYP3A4 interaction).
- 4Never stop without your oncologist’s instruction — early discontinuation allows rapid disease rebound.
- 5Storage: below 25°C, away from moisture, sunlight, and children.
Caregiver Guidance
- ♥Monitor blood pressure and pulse daily — this drug can trigger hypertension or atrial fibrillation. Keep a written log as advised by the care team.
- ♥Watch for bleeding: excessive bruising, nosebleeds, or cuts that are slow to stop. Report immediately.
- ♥Set a daily alarm and ensure no grapefruit is consumed. Have your pharmacist review all other medications for interactions.
If the Medicine Stops Working
Frequently Asked Questions
Do I need tests before starting?
How quickly does Ibruxen start working?
How long will I take it?
Can I stop if my scans look clear?
Will I lose my hair?
Can I take it with my other medicines?
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid oncologist prescription, in countries where the branded product is unavailable or unaffordable.
This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.
- Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated CLL. NEJM 2014;371:213–223.
- Woyach JA, et al. Resistance mechanisms for the BTK inhibitor ibrutinib. NEJM 2014;370:2286–2294.
- NCCN Clinical Practice Guidelines: CLL/SLL. V2.2026.
- Wang ML, et al. Ibrutinib in mantle-cell lymphoma. NEJM 2013;369:507–516.
